Overview

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

Status:
Recruiting
Trial end date:
2024-08-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme LLC